UK markets closed

MGC Pharmaceuticals Limited (MXC.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
3.7600-0.0600 (-1.57%)
At close: 4:35PM BST

MGC Pharmaceuticals Limited

1202 Hay Street
West Perth, WA 6005
Australia
61 8 6382 3390
http://www.mgcpharma.com.au

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Brett Anthony MitchellExec. Chairman199.44kN/A1973
Mr. Roby Reuven ZomerCo-Founder, CEO, MD & Exec. Director266.8kN/AN/A
Mr. Nativ SegevFounder & Non-Exec. Director248.05kN/AN/A
Mr. Amir PolakCTO & Head of Pharmaceutical ProductionN/AN/AN/A
Ms. Nicole GodresseGlobal Chief Sales OfficerN/AN/AN/A
Ms. Sabina SuljakovicHead of the Quality Assurance DepartmentN/AN/AN/A
Ms. Rachel Jelleff KerrCompany Sec. (Leave of Absence)N/AN/AN/A
Hugh WintersChief Exec. Officer of MGC DermaN/AN/AN/A
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLBJoint Company Sec.N/AN/AN/A
Mr. Paul CranneyExec.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

Corporate governance

MGC Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.